Skip to main content
Premium Trial:

Request an Annual Quote

Extending Deal, Lynx and Aventis CropScience Will Co-Develop Plant Assays

NEW YORK, April 1 - Lynx Therapeutics and Aventis CropScience will co-develop and commercialize an assay based on Lynx's bead-based technologies, the companies said today.
Terms of the collaboration, which extends by five years a deal the firms inked in March 1999 that gave the German ag-bio firm access to Lynx's genomics-discovery services, will give the companies joint ownership of the assay technology.

Lynx will manufacture and sell the services or products and will pay related royalties to Frankfurt-based Aventis CropScience. Lynx, of Hayward, Calif., will be paid for "performing genomics-discovery services" for Aventis CropScience during the deal's development and commercialization stage.

Further financial details of the agreement were not disclosed.

"We believe that initial results suggest that the use of our quantitative technologies will provide an excellent method for the development of effective assays for use in crops," Norrie Russell, president and CEO of Lynx, said in a statement. "We are excited about the extension of our agreement with Aventis CropScience, and we look forward to the commercialization of the assays."

The Scan

Alzheimer's Risk Gene Among Women

CNN reports that researchers have found that variants in MGMT contribute to Alzheimer's disease risk among women but not men.

Still Hanging Around

The Guardian writes that persistent pockets of SARS-CoV-2 in the body could contribute to long COVID.

Through a Little Spit

Enteric viruses like norovirus may also be transmitted through saliva, not just the fecal-oral route, according to New Scientist.

Nature Papers Present Method to Detect Full Transcriptome, Viruses Infecting Asgard Archaea, More

In Nature this week: VASA-seq approach to detect full transcriptome, analysis of viruses infecting Asgard archaea, and more.